Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1982 Sep;77(1):13–21. doi: 10.1111/j.1476-5381.1982.tb09263.x

Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.

J P Finberg, M Tenne
PMCID: PMC2044656  PMID: 6127132

Abstract

1 The degree of selective monoamine oxidase (MAO) inhibition produced by (-)-deprenyl, clorgyline, LY51641 and tranylcypromine was examined in relation to modification of tyramine and noradrenaline contractile responses of the rat isolated vas deferens. 2 All inhibitors possessed reversible alpha-adrenoceptor blocking activity, determined against noradrenaline on the denervated vas deferens. For LY51641 and tranylcypromine, antagonism was competitive, with pA2 values of 6.17 and 5.16. 3 Clorgyline, LY51641 and (-)-deprenyl (10(-5) M) inhibited the tyramine response while present in the organ bath: LY51641, which was the most potent as an alpha-adrenoceptor blocker, produced this effect at 10(-6) M. Responses to tyramine and noradrenaline were potentiated on wishing out the inhibitors, but noradrenaline potentiation was seen only when tyramine had been present in the system. 4 Tranylcypromine (10(-6) M) potentiated responses to noradrenaline and tyramine while present in the organ bath. 5 Potentiation of tyramine responses by clorgyline and LY51641 occurred at 91% and 64% inhibition of MAO type A respectively, although full potentiation of the tyramine response was elicited only when substantial inhibition of both enzyme types occurred. Selective inhibition of MAO type B by 67% (with deprenyl) was not associated with tyramine potentiation.

Full text

PDF
13

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BLACKWELL B. HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS. Lancet. 1963 Oct 26;2(7313):849–850. doi: 10.1016/s0140-6736(63)92743-0. [DOI] [PubMed] [Google Scholar]
  3. Birmingham A. T. Sympathetic denervation of the smooth muscle of the vas deferens. J Physiol. 1970 Mar;206(3):645–661. doi: 10.1113/jphysiol.1970.sp009035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chubb I. W., De Potter W. P., De Schaepdryver A. F. Tyramine does not release noradrenaline from splenic nerve by exocytosis. Naunyn Schmiedebergs Arch Pharmacol. 1972;274(3):281–286. doi: 10.1007/BF00501937. [DOI] [PubMed] [Google Scholar]
  5. Elsworth J. D., Glover V., Reynolds G. P., Sandler M., Lees A. J., Phuapradit P., Shaw K. M., Stern G. M., Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 1978 Apr 14;57(1):33–38. doi: 10.1007/BF00426954. [DOI] [PubMed] [Google Scholar]
  6. Finberg J. P., Tenne M., Youdim M. B. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981 May;73(1):65–74. doi: 10.1111/j.1476-5381.1981.tb16772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hendley E. D., Snyder S. H. Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy. Nature. 1968 Dec 28;220(5174):1330–1331. doi: 10.1038/2201330a0. [DOI] [PubMed] [Google Scholar]
  8. Jarrott B., Iversen L. L. Noradrenaline metabolizing enzymes in normal and sympathetically denervated vas deferens. J Neurochem. 1971 Jan;18(1):1–6. doi: 10.1111/j.1471-4159.1971.tb00161.x. [DOI] [PubMed] [Google Scholar]
  9. Johnston J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968 Jul;17(7):1285–1297. doi: 10.1016/0006-2952(68)90066-x. [DOI] [PubMed] [Google Scholar]
  10. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408. [PubMed] [Google Scholar]
  11. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm. 1978;43(3-4):177–198. doi: 10.1007/BF01246955. [DOI] [PubMed] [Google Scholar]
  12. Lader M. H., Sakalis G., Tansella M. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia. 1970 Aug 19;18(1):118–123. doi: 10.1007/BF00402391. [DOI] [PubMed] [Google Scholar]
  13. Neff N. H., Goridis C. Neuronal monoamine oxidase: specific enzyme types and their rates of formation. Adv Biochem Psychopharmacol. 1972;5:307–323. [PubMed] [Google Scholar]
  14. Riederer P., Youdim M. B., Rausch W. D., Birkmayer W., Jellinger K., Seemann D. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm. 1978;43(3-4):217–226. doi: 10.1007/BF01246958. [DOI] [PubMed] [Google Scholar]
  15. Sandler M., Glover V., Ashford A., Esmail A. The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena. J Neural Transm. 1980;48(4):241–247. doi: 10.1007/BF01250659. [DOI] [PubMed] [Google Scholar]
  16. Simpson L. L. Mechanism of the adverse interaction between monoamine oxidase inhibitors and amphetamine. J Pharmacol Exp Ther. 1978 May;205(2):392–399. [PubMed] [Google Scholar]
  17. Squires R. F. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol. 1972;5:355–370. [PubMed] [Google Scholar]
  18. Tallarida R. J., Cowan A., Adler M. W. pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 1979 Aug 20;25(8):637–654. doi: 10.1016/0024-3205(79)90505-8. [DOI] [PubMed] [Google Scholar]
  19. VAN ROSSUM J. M. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther. 1963;143:299–330. [PubMed] [Google Scholar]
  20. Youdim M. B., Collins G. G., Sandler M. Monoamine oxidase: multiple forms and selective inhibitors. Biochem J. 1971 Feb;121(3):34P–36P. doi: 10.1042/bj1210034p. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Youdim M. B., Collins G. G., Sandler M. Multiple forms of rat brain monoamine oxidase. Nature. 1969 Aug 9;223(5206):626–628. doi: 10.1038/223626a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES